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ABSTRACT 
INTRODUCTION:  
 Lung cancer is a highly aggressive malignancy causing high morbidity and mortality. 
An increasing incidence of lung cancer has been observed in India. For those with non-small 
cell lung cancer and patients with more advanced disease, targeted therapy has been a 
cornerstone of treatment. Several molecular markers in lung cancer has been introduced in 
the recent past. They are recent topics of interest which has emerged not only as a prognostic 
marker but also as markers to predict therapy response especially the EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR). The expression of this marker forms important 
criteria for  prognosis and therapy of lung carcinomas. The aim of this study is to assess the 
patterns of expression of EGFR and to assess the clinical and morphological characteristics of 
lung carcinomas. 
 
AIMS AND OBJECTIVES:    
 The aim of this study is to assess the expression of Epidermal Growth Factors 
Receptor (EGFR) in lung cancers. To compare the expression of EGFR with 
clinicopathological parameters in lung carcinoma. To assess the prognostic and predictive 
values of EGFR   
 
MATERIALS AND METHODS:  
 Out of 412 lung specimens received during the two year study period, 178 cases were 
non-small cell lung carcinoma. 60 cases are randomly selected for assessing EGFR 
expression which includes 20 cases each of adenocarcinoma, squamous cell carcinoma and 
non-small cell lung carcinoma-not otherwise specified(NSCLC-NOS). 
RESULTS:  
 68.33% of the cases are positive for EGFR expression.  90.48% of the females are 
positive for EGFR expression96.67% of the EGFR positive cases are smokers and 40% are 
non smokers. Among the EGFR positive histological subtype, adenocarcinoma is the most 
common type with 43.90% followed by squamous cell carcinoma with 36.59% & NSCLC-
NOS with 19.51%. 
CONCLUSION:  
 The identification of EGFR expression gives a fascinating opportunity for the 
development of tyrosine kinase inhibitors against non-small cell lung cancers. It is very clear 
from the comparison of various studies from our studies that EGFR expression is more 
common in females, never smokers and adenocarcinoma histological type. EGFR, being a 
poor prognostic factor, its expression is very important to identify the tyrosine kinase 
inhibitors sensitivity. Hence it is very important to find the association between EGFR 
expression and its clinocopathological parameters in order to select the patients for targeted 
therapy like erlotinib, gefitinib for advanced lung cancers. 
 In conclusion, it is recommended that EGFR expression should be a routine test  after 
lung resection for all non-small lung carcinoma especially adenocarcinoma and squamous 
cell carcinoma for better treatment for the patients. 
Key words: EGFR, Adenocarcinoma, Tyrosine Kinase inhibitors, Non-small cell lung cancers 
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INTRODUCTION 
 
 Worldwide it is estimated that lung carcinoma is the leading cause  of  cancer 
related mortality.  It is seen  most often in the age group of  40 to 70 years.  It 
constitutes around 12.5%  of all newly detected cancers and 17.8%  of  cancer  
related deaths (1). 
 It has been broadly classified mainly into two clinical subgroups. They are    
1. Non- small cell carcinoma of  lung and 
2. Small cell  carcinoma of lung, with  the  incidence  of about   80- 85%  and 
15- 20%  respectively(2). 
3. Non- small cell lung carcinomas  are further sub typed as  
4. Adenocarcinoma  (40% of lung cancers), 
5. Squamous cell  or epidermoid carcinoma  (25-30%), 
6. Large cell or undifferentiated carcinoma  (10-15%), 
7. Adenosquamous  type 
8. Sarcomatoid type  ( less common types ) (2) 
 
Thus it is clear that Non small cell lung cancer constitutes for  more than 85% 
of lung malignant cases out  of  which adenocarcinoma is the most common 
subtype.Only 15% of  lung cancer patients present with localised disease. Most 
patients present  with advanced  disease at the time of announcement of the disease. 
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For those with non small cell lung cancer and  patients with more advanced disease, 
targeted therapy has been a cornerstone of treatment The prognostic factors are 
age,sex,smoking status,stage,histology, histological grade.Several molecular markers 
in lung cancer has been introduced in the recent past. They are recent topics of 
interest which has emerged not only as a prognostic marker but also as markers to 
predict therapy response especially the EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR). The expression of this marker forms important criteria for  
prognosis and therapy of lung carcinomas.The aim of this study is to assess the  
patterns of expression of  EGFR and to assess the clinical and morphological 
characteristics of lung carcinomas.  
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AIMS AND OBJECTIVES 
 
 To assess the expression of  Epidermal Growth Factors Receptor (EGFR) 
in lung cancers.  
 To compare the expression of EGFR with clinicopathological parameters 
in lung carcinoma. 
 To assess the prognostic and predictive values of EGFR    
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REVIEW OF LITERATURE 
Epidemiology 
Lung carcinoma has become very frequent cause of mortality and morbidity  
in and around the world and it has become the most important cause of death in 
industrialized countries. Though lung cancer has been strongly associated with the 
usage of tobacco, it is increasing in females in the recent years. It is said that more 
than 90% of patients are over the age of 40 years at the time of diagnosis(3) 
1.8 million new cases have been diagnosed in 2012 with highest age 
standardized rates in central Europe & eastern Asia. Incidence rate is low in western 
& middle Africa.It is calculated that nearly one in every five cases of death is due to 
lung cancer which accounts for 19.4% of all deaths(4) 
           In India, lung carcinoma is more common and severe among males. The 
incidence rate is relatively low among Indian Women(4) 
Etiology & Pathogenesis 
Tobacco Smoking 
Among all the risk factors estimated, smoking is the most important 
etiological factor associated with this malignancy. There are many evidences to 
prove that there is a strong statistical association between the increased incidence 
rates of lung cancers. Most of the carcinomas of lung are associated with smoking. 
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It depends upon the smoke inhalation depth, number of packets of cigarettes 
smoked eachday and the duration of  smoking years. We all know that 
procarcinogens are converted to carcinogens through activation of P450 
monooxygenase enzymes. Cigarette smoke has P450 monooxygenase enzyme 
system which has increased capacity to activate procarcinogens. 
Pipes and cigars smoking also increases the risk. 
There is a strong linear correlation between the appearance of epithelial living 
changes and tobacco smoking intensity. The changes seen in order are squamous 
metaplasia, Carcinoma in Situ and invasive carcinoma(5). Second hand smoke or 
passive smoking also increases the risk(6,7,8). 
The etiology of lung carcinoma in multifactorial as explained by the lung 
cancers in non-smokers. Environmental and genetic factors also play important role. 
Air pollution 
Air pollution increases the risk of lung cancer. Air particulates in smog, when 
exposed chronically causes lung irritation, inflammation and repair. Repeated 
inflammation can lead to lung cancer. Radan, which is a radioactive gas causes 
increased risk of lung cancer and it has been estimated to be the second most 
important cause for lung cancer in Unites States(9,10,11). 
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Industrial hazards 
Industrial exposures like chromium, arsenic, uranium, nickel, asbestos 
increases the risk of developing lung malignancies. Uranium, which is a weak 
radioactive substance, causes four times increased risk. 
The latent period before the exposure of asbestos and lung cancer is 10-30 
years. Asbestos workers are at 50-90 times increases risk than the non-smokers(12,13). 
 
Radiation therapy 
Patients who are given radiation therapy as treatment for malignancies like 
Hodgkin disease and breast carcinoma are at increased risk for lung carcinoma(14). 
 
Geographical location 
Areas like South-America and South-Asia where people are exposed to 
increased levels of arsenic in drinking water are at increased risk(14). Certain 
histological types are seen in particular geographical areas than the others, as for 
example adenocarcinoma is more common in the Unites States and squamous cell 
carcinoma is more common in white women when compared to black women. 
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Molecular genetics 
Oncogenic ‘driver’ mutations which when accumulate can cause neoplastic 
transformation of the epithelial cells of lung. There are various histological 
subgroups and each of them have distinct molecular features. 
Adenocarcinoma 
They are characterized by gain of function mutation in EGFR, ALK, ROS, 
MET and RET. 
Small Cell Carcinoma 
Often shows loss of function in TP53 and chromosome 3p deletion. 
Squamous cell carcinoma 
These are characterized by losses in 3p, 9q, 17p loss of expression of 
retinoblastoma (RB) gene. 
ANATOMY AND HISTOLOGY OF LUNGS: 
There are two main components of the lung parenchyma, bronchi and 
bronchioles and the alveoli. They are paired intrathoracic organs. There are three 
lobes on the right lung and 2 on the left lung. There is a rudimentary appendage from 
the upper lobe of left lung which is called lingulae. 
Trachea divides into 2 bronchi which in-turn divides into bronchioles, 
terminal & respiratory bronchioles. The respiratory tract is lined by pseudostratified 
ciliated columnar epithelium. 
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Type 1 & type 2 pneumocytes line the alveoli. Neuroendocrine cells, Clara 
cells, alveoli cells, ciliated cells and goblet cells are other cell types in bronchial-
bronchiolar epithelium. 
 
ORIGIN 
The site of origin for lung cancer refers to the type of tissue from which the 
cancer cells develops(15,16). Usually lung cancer is categorized by its site of origin 
into hilar and peripheral types, as these structures from where the disease originates 
are different . The majority of  the early lung cancers arising in  hilar regions are 
squamous cell carcinoma, whereas those early stage  cancers arising in the peripheral 
areas of lung are adenocarcinomas(17). Adenocarcinomas usually originates in 
glandular tissue whereas squamous cell carcinoma originates in the tissue which 
lines the organs and tubes of the lungs called epithelial tissues(18).  NSCLCs  such as  
adenocarcinomas and large cell lung carcinoma are located typically in the 
peripheral areas of  lungs and can present as  either solitary nodule or masses(17). 
Squamous cell carcinoma and small cell carcinoma   are normally found to arise in 
the central portions of the lung and may be misdiagnosed as  collapsed lung 
(Atelectasis) or pneumonia(17). Small cell carcinoma are usually located in the main 
bronchi. this  type of malignancy appears to originates from the Kulchitsky cells, 
which in turn is a  component of the bronchial epithelium(17) 
 
 
9 
 
Histological types 
There are several histopathological subgroups of lung cancer. 
The major categories are 
• Squamous cell carcinoma 
• Small cell carcinoma 
• Adenocarcinoma  
• Adenosquamous carcinoma 
• Large cell carcinoma 
• Sarcomatoid carcinoma 
• Carcinoid tumor 
• Carcinoma of salivary gland type 
• Unclassified carcinoma 
Squamous cell carcinoma  
This particular histological type has strong association with exposure to 
tobacco smoke and genetic association like loss of 3p, 9q & 17p. Among all the 
histological types of lung carcinoma, SCC has high association with TP53 mutation. 
Most of the patients present as hilar/perihilarmass. But they can also be found in 
peripheral & subpleurallocation(19,20). If present in such location, tumor cells may fill 
the alveolar Lumina in a lepidic like fashion(21). Malignant cells are seen exfoliated 
in the sputum or brushing cytology. They can undergo necrosis along with 
cavitation. Sometimes they present as intrabronchial polypoid masswith few minor 
extra bronchial spread(22,23). 
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The tumor is also seen to penetrate into the wall of bronchus and infiltrate into 
the peribronchial tissue. 
In H&E examination, diagnosis is based on cell atypia and invasiveness. It is 
characterized by keratinization with or without intercellular bridges. These features 
are more prominent in well-differentiated tumors whereas mitotic activity and atypia 
increase in poorly differentiated tumors. 
Thus they are divided into well, moderate & poorly differentiated carcinoma 
on the basis of degree of keratinization. There are various subsets like 
• Small cell variant 
• Clear cell variant 
• Well-differentiated papillary variant 
• Basaloid variant 
• Spindle cell/carcinosarcoma 
 
Variants of scc: 
Papillary variant: 
This variant of squamous cell carcinoma shows exophytic and endo-bronchial 
growth invasion  in most of the cases. But sometimes limited intra-epitheial spread 
without invasion is seen(24) 
Clear cell variant: 
This variant of scc contains most malignant cells featuring classical  clear 
cytoplasm(25) 
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Small cell variant:  
These are  poorly differentiated SCC with small tumour cells which  retains 
the morphological characteristics of NSCLCs  but with focal squamous 
differentiation(26,27) 
 
Basaloid variant: 
 This  squamous cell carcinoma variant  shows peripheral  palisading of nuclei 
which is the prominent finding and it usually presents with very aggressive clinical 
course. Squamous cell carcinoma have better survival rate  than adenocarcinoma(28) 
Electron microscopy shows abundant tonofilaments and basal lamina 
formation(29,30). 
On IHC, there is strong reactivity for low & high molecular weight keratins & 
involucrin(31,32,33). Also positive for vimentin EMA, S100, desmocollin-3(34)& 
glypican-3. 
Adenocarcinoma 
They are seen most commonly in over half of all lung carcinomas in females 
and a few percentage in males(35,36). Its incidence is increasing in the last 2 decades, 
most of them present as poorly circumscribed grey-yellow lesions. 
Sometimes, a small peripherally presenting adenocarcinoma spreads 
extensively into the pleural space and coats both the pleural layers simulating the 
appearance of diffuse mesothelioma(Pseudomesotheliomatous carcinoma)(37-40). 
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Rarely they can be present as a large endobronchial polypoid mass(41). Sometimes a 
large number of cases of adenocarcinoma arising in association with a peripheral 
scar or Honey combing may show areas of atypical bronchiolar and alveolar 
proliferation in neighboring air spaces(42-47). 
On microscopy they show a spectrum of differentiation which on one extreme 
blends with bronchio alveolar carcinoma and other end with undifferented large cell 
carcinoma. The formation of tubular or papilla and secretion of mucin are the two 
signs of glandular differentiation. Depending on the predominance of these features, 
they can be subdivided into acinar, solid, papillary, micro papillary, signed ring type. 
Rare variants are adenocarcinoma with goblet cell type(48,49,50), hepatoid 
type(51,52)adenocarcinomawith choriocarcinoma foci(53), adenocarcinoma with 
rhabdoid features(54), microcystic adenocarcinoma(55), and adenocarcinoma with 
massive lymphocytic infiltration(56). On IHC, they are positive for low molecular 
weight keratin, CEA, EMA, & members of MUC family(57-60). They are associated 
with genetic features like TP53 alteration, p16/CDKN2A inactivation, disruption of 
RB pathway(61), loss of 3p, KRAS , EGFR and C-MET mutation. 
Histological subtypes of adenocarcinoma: 
1. Mixed Type :    
 Most common type of adenocarcinoma representing 80% of resected 
specimens. 
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2. Acinar Pattern:   
 It contains tubules and acini composed of columnar or cuboidal cells which 
may secrete  mucin(28) 
3. Papillary Pattern : 
 In this type  secondary  and tertiary papillary structures are seen which 
replaces the underlying lung architecture. Tissue invasion and necrosis may be 
present. The lining cells may be mucinous and non-mucinous secreting cuboidal to 
columnar cells. Micropapillary  pattern of  adenocarcinoma, are usually  
prognostically unfavourable varieties(62) 
4. Bronchoalveolar pattern : 
 In this pattern malignant cells will grow along the alveolar structures (this is 
known as lepidic growth). but without  vascular, stromal,  or pleural invasion(28) 
5. Solid Pattern:   
 This variety composed  usually of polygonal cell sheets which lacks tubules 
acini  and papillae but  mucin is seen in atleast five tumour cells. 
Large cell carcinoma 
Undifferentiated or large cell carcinomas are pleomorphic malignant 
epithelial tumors without any squamous or glandular differentiation(63). Its location 
along with electron microscopy and IHC features suggests that they mostly resemble 
adenocarcinoma(64-68). Some cases are associated with marked peripheral 
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eosinophilia or leukocytosis(69,70) due to granulocyte colony-stimulating factor 
produced by the tumor. 
The variants of this tumor are 
• Giant cell carcinoma 
• Lymphoepithelioma like carcinoma 
• Large cell neuroendocrine carcinoma 
• Non-small cell lung carcinoma with neuroendocrine features. 
• Combined large cell neuroendocrine carcinoma. 
• Basaloid carcinoma 
• Clear cell carcinoma 
• Large cell with rhabdoid phenotype. 
Variants : 
1.Large cell neuroendocrine carcinoma : 
This type constitutes 3% of lung cancers(71). The malignant cells are 
arranged in various patterns such as organoid, nesting, trabecular rossetes  or 
peritubular  palisading  patterns(28,72). The cells are usually large with  abundant 
cytoplasm and nucleus shows  prominent nucleoli. 
2. Combined large cell neuro endocrine carcinoma : 
          This tumor shows combination of features  of  squamous cell carcinoma,  
adenocarcinoma, giant cell carcinoma  and  may be spindle cell carcinoma too. 
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3.Basaloid carcinoma: 
          Here, the tumor cells are arranged in many patterns as  nodular, solid,  
trabecular,  and invasive growth pattern . Peripheral palisading of cells may be 
noted. The cells are monomorphic, small cuboidal to fusiform with  nuclei 
showing  moderate hyperchromatism(73) 
4.Lymphoepithelioma like carcinoma: 
          They show growth pattern, with tumor cells having large vesicular nuclei, 
and prominent nucleoli. This type of carcinoma show heavy lymphatic 
infiltration(71,72) 
5. Clear cell carcinoma: 
Large polygonal  tumour cells with clear, foamy cytoplasm(74,75) 
6. Large cell with rhabdoid phenotype: 
Rhabdoid cells containing tumour in which this rhobdoid cells should 
constitute atleast 10% of tumour cells. 
Small Cell carcinoma 
They constitute 10-20% of all lung cancers and most of them are males with 
the median age of 60 and most of them are smokers. Typically, they present in 
central position of the lung, but rarely in peripheral location(76,77). 
 The epithelial cells are very small, with scant cytoplasm, granular nuclear 
chromatin and inconspicuous nucleoli. Azzopardi effect which is characterized by 
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staining of vascular walls by intense basophilic staining due to encrustation caused 
by DNA from necrotic tumor cells which are frequently present. 
Electron microscopy shows densecore neurosecretory granules.  
Immunohistochemically, they are positive for Bcl2 and mutation of p63 and 
RB tumor suppressor genes are commonly present. 
 Combined small cell carcinoma : 
 A tumour with characteristics  of small cell variety with additional small 
components of either squamous cell carcinoma or adenocarcinoma. This type usually 
appears as hilar or periphral mass lesions or often presents with mediastinal  
lymphadenopathy and or lobar lung  collapse. 
AdenoSquamous carcinoma  
This type of lung cancers shows evidence of malignant features in both 
squamous and glandular differentiation in an almost equivalent amount(78). They 
account for less than 10% of all lung tumors. Most of them are seen located 
peripherally and associated C scar. 
Sarcomatoid carcinoma & carcinosarcoma 
It is a family of carcinoma having sarcoma like features when it contain 
predominantly of spindle shaped cells and proved on EM and IHC, they are called 
spindle cell or sarcomatoid carcinoma(79-83). 
Grossly, they present as intraparenchymal or intrabronchial polypoidal mass. 
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On H&E, epithelial elements are present along with sarcoma like component 
which can resemble fibro sarcoma, MFH like appearance chondrosarcoma, 
osteosarcoma, RMS or angiosarcoma. 
On IHC, they are positive for pankeratin, EMA and p63. 
Clear Cell Carcinoma 
It is a type of lung carcinoma composed  of cells predominantly with clear 
cytoplasm. These clear cells contain abundant glycogen. 
Adenocarcinoma and related tumors 
They can present as single or multiple modules and a diffuse pneumonic like 
infiltrate(84-86). 
On microscopy, they can be divided into mucinous and non- mucinous type. 
The mucinous type has a typical glistening appearance on gross. 
Microscopically, the tumor is composed of well differentiated mucin 
containing columnar cells in a ‘lepidic’ fashion without stromal invasion. 
           The non-mucinous type has a gray-white foci of parenchymal consolidation. 
Microscopically, they also show lepidic pattern without stromal infiltrate and the 
tumor cells are cuboidal rather than columnar and have brighter eosinophilic 
cytoplasm nuclear atypia and nucleolar prominence is greater than that seen in 
mucinous type. PAS positive eosinophilic intranuclear inclusions are seen. 
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Other rare types of lung cancers: 
There are many rare types of lung cancers like sarcomas, lymphomas, 
adenoidcystic carcinoma, mucoepidermoid carcinoma and epithelial-myoepithelial 
carcinoma. 
Precursor lesions 
It has been said for a long time that squamous cell lung malignancies have a 
long preclinical stage where the lesion progresses from mild, moderate & severe 
dysplasia to carcinoma in situ, mircoinvasive carcinoma and frank invasive 
carcinoma. 
Grossly they show granularity, papillation and loss of rugae. On H&E, they 
show full thickness involvement with intact basement membrane. Loss of 
heterozygosity, at 3p and 9q are seen in squamous metaplasia and dysplasia followed 
by TP53 mutation in carcinoma in situ. Squamous dysplasia / carcinoma in-situ:  
This represents the precursors of  SCC of lung. 
• Atypical Adenomatous hyperplasia (AAH) :  
 This adenomatous hyperplasia represents the precursor lesion for 
adenocarcinoma . it usually seen in peripheral lesions  and 
• Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: 
 This may progresses  to carcinoids. Other possible pre-neoplastic lesions are 
Squamous metaplasia (which progresses to squamous dysplasia,carcinoma in situ ), 
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Adenomatous hyperplasia (precursor to AAH),   Basal cell hyperplasia, pulmonary 
fibrosis,  angiogenic  squamous  dysplasia, etc(87) 
No precancerous lesion is identified for small cell carcinoma so far. But 
sometimes precursors of NSCLSs such as squamous dysplasia  or carcinoma in-situ 
be seen in the nearby airway mucosa(87) 
Clinical features: 
Lung malignancies usually present with symptoms like cough, hemoptysis, 
chest pain, hoarseness of voice, loss of weight, loss of appetite, new onset of wheeze 
(commonly seen in squamous cell carcinoma). 
Small cell carcinoma present with symptoms according to the site of distant 
metastasis. 
Adenocarcinoma  are  usually  asymptomatic  and  it  is more often a 
incidental radiological finding. 
Obstructive pneumonia, pleural  effusion, chest pain, back pain are the local 
effects of the tumor and they are due to mediastinal invasion by the tumor. 
Entrapment of nerves like recurrent laryngeal nerve can cause hoarseness,  
horner syndrome is due  to sympathetic nervous system and diaphragmatic paralysis 
is due of entrapment of phrenic nerve. 
Superior vena cava obstruction can cause superior vena cava syndrome. 
Cardiac tamponade and pericarditis are caused due to pericardial 
involvement.Dysphagia occurs due to oesophagus involvement. 
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The symptoms due to metastasis depends on the organ of involvement by the 
tumour.  Infiltration of liver, pancreas and adrenals cause symptoms like loss of 
weight and abdomen pain. 
Bone pain is present if it involves the bone.Neurological symptoms like 
headache, dizziness and vomiting are due to the central nervous system involvement 
by the tumour. 
There are many paraneoplastic syndromes associated with lung carcinomas 
like hypercalcemia, hypocalcemia, carcinoid syndrome, cushing syndrome, 
gynacomastia etc 
Systemic manifestations: 
Antibodies directed against the neuronal calcium channels(88) cause Lambert- 
Eaten syndrome. It causes symptoms like neuropathy, acanthosis nigricans, 
hypertrophic pulmonary osteoarthropathy. The hematological symptoms caused are 
anemia, thrombocytopenia, eosinophilia, leukemoid reaction, leucoerythroblastosis 
etc. 
Disease course: 
Dysplasia usually preceeds the disease course for years which is followed by 
carcinoma in situ which lasts for several years and presents as a mass which is 
aymptomatic in the beginning and presents with symptoms in the latter. The lesion 
presents with hard grey white lesions with some areas of hemorrhage and 
necrosis(18). 
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Lung carcinomas can present as lesion within the lumen. It can penetrate the 
wall of the bronchus and involves the peribronchial tissues, carina and mediastinum. 
Local spread to the pleura, pericardium and the regional lymphnodes like 
tracheal, bronchial and mediastinal lymph nodes can occur. 
Lymphatic and hematogenous routes are the ways of spread to cause distant 
metastasis. Most of the tumors metastasise early except squamous cell carcinoma 
which metastasise late. 
Distant metastasis is common to the adrenals which constitutes more than 
50% and followed by liver, , bone and brain respectively(89). 
Role of Imaging studies in lung cancer: 
Imaging should be done both pre operatively and post operatively for the 
following reasons 
 To find a suspicious lesion in the lung which turn out to be malignant 
 Used for the staging of the disease 
 To assess the effectiveness of the treatment 
 To look for recurrence of the tumor 
There are various imaging modalities that are used for diagnosing of lung 
malignancies. They are 
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X-ray: 
It is the most preliminary and basic investigation used for identifying lung 
malignancies. It helps to assess the involvement of main bronchi and trachea. It also 
helps in identifying lymphadenopathy, mediastinal invasion and pleural effusion. 
Computed tomogram ( CT ): 
         It helps to localize the site of involvement of tumour. The size and shape of the 
tumor can be assessed. Also the regional sites of involvement of the tumor and 
metastatic sites of involvement like liver, brain, bone adrenal can be assessed. 
Magnetic resonance imaging(MRI): 
It can identify lesions of metastatic sites like brain, spinal cord etc. 
Ultrasonogram (USG): 
It helps to detect pleural effusion. It also guides for investigations like 
thoracocentesis and for biopsy of peripheral lung lesions for tissue biopsy. 
Positron emission tomography(PET SCAN): 
It is a method of nuclear imaging which can detect the biochemical changes in 
the body tissues. 
           More commonly it is used as a whole body scan which detects the tumor 
recurrence and early breast lesions. 
          Staging of lung cancer has been improved with the advancement of this 
technique(90-92). 
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Bone scan: 
It is used to identify bone involvement. 
Investigations for lung cancer: 
The gold standard test for diagnosis of lung malignancies is by 
histopathological examination of lung tissue specimens. The diagnostic modalities  
used are 
9 Cytology of sputum specimens 
9  Thoracocentesis 
9 Flexible bronchoscopy 
9 Transthoracic needle aspiration  
9 Thoracotomy(93) 
9 Video assisted thoracoscopy 
9 Excision biopsy of nodes 
The treating physician should determine the suspicious type of lung cancer in 
order to select  the appropriate test procedure. 
Patients suspected to have early lung cancer can be evaluated with 
thoracotomy. Histopathological examination and staging can also be estimated with 
this method. 
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Sputum examination: 
For sputum cytology examination, atleast three sputum samples are 
examined(94,95). Adequacy of sputum sample is identified by the presence of alveolar 
macrophage, squamous cells 
Minimum of three sputum samples are examined. It is a noninvasive test. 
Hence other procedures can be proceeded if it is negative. Sputum cytology 
examination is very important for patients presenting with hemoptysis. It is 
recommended for centrally located tumours. Specificity of sputum cytology in the 
diagnosis of lung cancer is about 98%. Sensitivity for centrally located tumors is 
71% and peripherally located tumors is less than 50%(96,97). It is also helpful to 
diagnose squamous cell carcinoma. 
Thoracocentesis: 
In patients presenting with pleural effusion, thoracocentesis can be done. 
Pleural fluid can be evaluated for malignancies by careful sampling. The sensitivity 
and specificity of diagnosing lung cancer using thoracocentesis  is 80% and 90% 
respectively. 
Excision biopsy of lymph node: 
If the lymph node is in a accessible site, excision biopsy of the entire node is 
done to for histopathological examination. 
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Flexible bronchoscopy: 
           The sensitivity of this test is 88%. Flexible bronchoscopy is done by passing 
the bronchoscope through the bronchial lumen and advancing the scope to visualize 
the lesion, if any. Bronchial wash and tissue for examination is collected. 
According to De Wever W et al(90), catheter placement into the  patients lung 
should not be attempted without the assistance of computed tomography. The 
sensitivity and specificity of the investigation depends on on the site of location of 
tumor and its size. The sensitivity of diagnosing centrally located tumor is higher 
than the lesions presenting peripherally which are 90% and 70% respectively.  
Transthoracic needle aspiration: 
CT or fluoroscopy guided transthoracic aspiration can be done with the 
appropriate needle size. This is the recommended procedure of choice for 
peripherally located lesions. The sensitivity and specificity of this method is 90% 
and 97% respectively. This procedure is done in cases where the transneedle 
aspiration is not conclusive for a patient with peripheral tumor. Also done for 
patients who are not suitable for surgery. Pneumothorax which is the most common 
complication of this procedure  is seen in 25% to 30% of patients undergoing this 
procedure.  
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Video assisted thoracoscopy: 
Tumors of size less than 2 cm that are peripherally located pleural tumors, 
pleural effusion can be done with video assisted thoracoscopy. Endoscopies help to 
assess and visualize the space between the lung and peripheral pleura. It helps in 
identifying small lesions in the interpleural space and to take tissue biopsy. It is also 
useful to resect  the tumours at the early stage. The major advantage of this 
procedure is that we can prevent the attempt of thoracotomy. 
Thoracotomy: 
If the tumor is resectable, thoracotomy is the recommended method for 
diagnosis of early stage disease(90).  
Biopsy 
With the advent of fiber optic bronchoscopy, it has dramatically expanded the 
potential of bronchoscopic biopsy. The instrument is easily inserted and can be well 
accepted by the patients. If the clinical suspicion is high and bronchoscopic biopsy 
fails to establish the diagnosis of carcinoma, an exploratory thoracotomy can be 
done. 
Cytology 
Sputum and/or bronchial brushings can make a diagnosis in 80-90% of 
patients with lung carcinoma. False positive diagnosis are seen in infarct, 
bronchiectasis, mycotic infection, viral pneumonia, irradiation changes and lipoid 
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pneumonia. Macrophages, altered alveolar lining cells or mesothelial cellscan be 
misinterpreted as malignant. 
The reports can be as 
• Unsatisfactory (no macrophages) 
• ‘Negative’ (no abnormal cells) 
• ‘Benign atypia’ (epithelial bronchial cells with hyperplastic & metaplastic 
changes secondary to inflammation) 
Suspicious but not diagnosed (Indication to repeat) 
• Positive for malignant cells. 
Frozen section 
It is mostly recommended for peripheral lesions where the tumor can be 
excised with a margin of normal lung. Also when it is proved to be a benign lesion 
like hamartoma or organizing pneumonia. 
                  The two important contribution of frozen section for lung carcinoma are 
mapping of mediastinal & hilar lymph modes and estimating the bronchial margins 
for tumor cells. 
Screening: 
As there are many histological patterns of lung cancer, a single biomarker for 
diagnosis is a great challenge. Many biomarkers are evaluated. An effective 
screening should be such that it should identify cases at an early stage so that 
survival can be improved. Moffitt cancer research(98,99) centre has a project which 
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emphasizes on screening procedure. Monoclonal antibodies is one of the screening 
method which can be followed. Our recent research topic of interest has been the 
identification of monoclonal antibodies and their staining intensity. The expression 
of these genetic and protein markers help in understanding the cell of origin and their 
tumour biology. Mutation of a particular gene can cause specific epithelial 
malignancies. These mutated genes  induces abnormal cell growth and proliferation. 
An early marker used for the early detection of lesions of lung cancer in sputum 
cytology is Heterogenous nuclear ribonucleoprotein(hnRNP). There are many datas 
which explains the that hnRNP is expressed in most lung cancers before any 
morphological abnormality could be identified.  
       There are many other lung markers which are useful in for cancer screening. 
They are tumor suppressor genes like p53, p16, p21, Rb, proto-oncogenes like c-
myc, K-ras, HER2 NEU, HGF, growth factors are TGF-b, FDGF, apoptotic factors 
like Bcl-2, factors of angiogenesis like VEGF and gene amplification factor like 
HER-2(98). These markers are very useful for identifying lung carcinomas. Also these 
markers are used for the identification of prognostic and theraupeutic markers. There 
are many biological markers which are found to be strongly associated with various 
lung malignancies. 30% of non small cell lung cancer is strongly associated with 
retinoblastoma gene and nearly 100% of cases of small cell lung carcinoma is 
associated with retinoblastoma gene.  
There are various clinical trials conducted on a large scale to find out the 
efficacy of screening methods in lung carcinoma. One such trial is the one conducted 
by National Cancer institute. The main focus of this study was to identify the 
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effective methods for screening and to identify the mortality and morbidity rates of 
various specific types of lung malignancies. The main disadvantage encountered in 
this trial was that the conventional x-rays fail to diagnose lung neoplasms at an early 
stage(100). National Lung Screening Trial is another such kind of trial for evaluating 
the screening methods. This trial compares the efficacy of conventional x-rays and 
spiral CT scans for the screening of lung cancers. It has been evaluated that spiral CT 
scans can detect lung nodules which cannot be picked up by conventional x-rays. 
Thus spiral CT scans are proved to diagnose lung cancers at early stage and thus 
helpful to detect lung malignancies.  
Spread and metastasis 
Lung cancer spreads by direct extension proximally & distally along the 
bronchus of origin and invades the trachea. Pleural effusion is very common when 
they invade the chest wall and diaphragm. Invasion of blood vessels can sometimes 
cause extensive tumor emboli. 
Lymph node metastasis first occur in the hilar region followed by 
mediastinum, supraclavicular groups, axillary & subdiaphragmatic sites. 
Distant metastasis are seen in liver, other parts of lung, adrenal, bone, kidney 
& Bone marrow. 
 
 
 
30 
 
CLASSIFICATION OF LUNG CANCER: 
In the past lung tumors has been classified into small cell carcinoma of  lung  
and non small cell lung malignancies based on the available modality of treatment 
options. But in the recent past, due to the availability of personalized medicine and 
targeted therapies, it is important to identify the specific subtypes of non small cell 
subtypes so that advanced treatment options can be used. The discovery of specific 
gene alterations, particularly those responding to tyrosine kinase inhibitors has 
necessitated the need for revising this older classification. The most frequent 
molecular alterations encountered in lung carcinomas are epidermal growth 
receptor(EGFR), K-RAS genes, rearrangements of anaplastic lymphoma kinase 
(ALK) genes. The expression of EGFR genes correlates with better response to 
treatment modalities particularly in adenocarcinoma. K-RAS mutations is also 
expressed in 15-30% of lung adenocarcinomas which is a marker to denote the 
resistance of lung carcinoma to tyrosine kinase inhibitors. This approach has led to 
the necessity of inclusion of molecular genetic classification(101,102). 
WHO CLASSIFICATION OF LUNG CANCER: 
(ANNEXURE II) 
The most widely used method of histological classification is proposed by 
World Health Organisation(WHO).  
       Though it is widely accepted method of classification, it has some interobserver 
variability for which certain subtypes are not associated with molecular 
characteristics.    
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             It is broadly classified as malignant epithelial neoplasms, biphasic epithelial 
mesenchymal neoplasms, mesenchymal neoplasms, lymphoproliferative neoplasms 
and metastatic tumors. It is explained in ANNEXURE.  
IASLC/ATS/ERS Classification in small biopsy and cytology: 
(ANNEXURE III) 
Treatment: 
      There are four basic modalities of treatment for the trearment of lung cancer. 
They are  
 Surgery  
 Chemotherapy 
 Radiotherapy and  
 Targeted therapy 
 
The treatment for different types of lung cancers depends on the histological 
type of lung cancer, stage at presentation, patients preference, side effects of 
particular treatment and health of the patient.  
The standard therapy done for operating non-small cell lung carcinoma is 
complete surgical excision through thoracotomy(103-105). Combined modality 
treatment is done for tumors of high grade. Radiation therapy can be done with 
effective results to control local growth of lung cancer. 
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The various types of surgeries done are lobectomy, segmentectomy, 
pneumonectomy and wedge resection. 
Chemotherapy and concurrent radiotherapy can be done for patients with 
early stage small cell lung carcinoma. 
Surgery can no longer be done once the tumour has started spreading beyond 
the hemithorax and metastasized to the lymph nodes. Chemotherapy and 
radiotherapy are the only modality of treatment in such cases. 
The two types of radiotherapies given in lung cancer are radioisotope therapy 
and external beam radiotherapy. 
           The chemotherapy drugs used are platinum based cisplatin, carboplatin and 
non platinum based drugs like Doceraxel, Paclitaxel, Gemcitabine etc. 
           Chemotherapy is the only modality of treatment in distant metastasis. 
           Targeted therapy is of much benefit when given to appropriate patients. In 
targeted therapies, treatment is given against the specific genes or specific proteins. 
Currently it is recommended that EGFR mutation to be documented in lung 
cancer cases. It can be done by mutant specific EGFR antibodies or PCR. EGFR 
mutations are seen in 10-15% of cases of non small cell lung cancer. It is most 
commonly seen in adenocarcinoma type of lung malignancies. 
There is a significant advancement in the treatment of lung cancer due to 
tyrosine kinase inhibitors like gefitinb and erlotinib which acts as targeted therapy in 
patients with EGFR mutation. 
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Another targeted therapy is vascular endothelial growth factor inhibitor such 
as bevacizumab. This antiangiogenesis therapy blocks the development of new blood 
vessels and helps in treatment management. 
Around 5% of non small cell lung carcinoma is is associated with 
rearrangements of ALK gene. It is seen commonly in non smokers and in patients 
with adenocarcinoma.  
There are many other markers for targeted therapy like like BRAF, FGFR, 
HER2, K-RAS, ROS1. 
 
 
 
 
 
 
 
 
 
 
 
 
  
No
 
 
Pr
ma
Ear
can
of 
n small ce
ognostic fa
As m
lignancies
ly detectio
cer is qui
al maligna
ll lung ca
ctors: 
ost of t
 at early s
n of canc
te difficult
ncies. Mo
rcinoma- 
he screen
tages, ear
er is helpf
 for lung m
rtality rate
34
treatment
ing progr
ly detectio
ul in impr
alignanci
 is increase
 in advanc
ams are 
n of canc
oving the 
es, it has 
d when co
ed stage: 
unsucces
er is not p
survival. A
become on
mpared to
sful in i
ossible in
s early de
e of the m
 other ma
dentifying
 all cases.
tection of
ost lethal
lignancies
 
 
 
 
 
 
35 
 
like colon, prostate and breast malignancies. The major drawback of this malignancy 
is that most cancers are asymptomatic till the advanced stage. American cancer 
society has estimated that only 15%  of the lung malignancies are identified at early 
stage. The five year survival of lung carcinoma is 15%. It is because of lack of 
effective screening programmes. 
There are many factors which affect the prognosis of lung cancer 
Age :  
Patients less than 40 years have poor prognosis. This is because  they  present 
with advanced disease and aggressive behaviour(106). 
Sex: 
Women have higher incidence of advanced lesions & adenocarcinoma is the 
most common type of histological type  and have worse prognosis 
Location:  
Tumors of superior pulmonary sulcus have a better prognosis than others. 
Squamous cell malignancies that are located peripherally have better prognosis than 
the carcinomas that are located centrally(107-110). 
Stage:  
TNM staging is the single most important parameter for lung cancer(111,112). 
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Tumor size:  
Large size tumors have worse prognosis than the small size tumors of same 
histological type(113). In adenocarcinoma type of lung malignancies showing both in-
situ and invasive component, the site of invasive component is the single most 
important predictor of survival rate. 
Histological type & Differentiation:  
The most curable type of lung carcinoma is squamous cell carcinoma(114-
116).The five years survival rate for well differentiated carcinoma is 40%, for 
moderately differentiated tumors it is 20%, and for  the poorly differentiated 
malignancies, it is 7%. 
In adenocarcinoma type, micropapillary pattern has worst prognosis(117-119). 
Prognosis of BAC is found to be better than ordinary adenocarcinoma. 
Large cell carcinoma having tumor giant cells have worse prognosis. 
           Small cell carcinomas have worse prognosis compared to other type of lung 
malignancies. Their five year survival rate is less than 2%. 
Chest wall invasion: 
The risk of operative mortality is higher than in cases with chest wall 
invasion(120). 
Blood vessel invasion:  
They have ominous prognostic significance. 
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Pleural effusion: 
The pleural fluid positive for tumor cells is a poor prognostic indicator(121). 
Presence of scar: 
Tumors with scar has worst prognosis than tumors without scar. 
Lymph mode involvement: 
It is one of the most important prognostic factors. 
Inflammatory reaction:  
The presence of lymphoplasmacytic infiltrate is a favorable prognostic 
sign(122). 
Rhabdoid features: 
It has a very aggressive behavior(123). 
TTF-1: 
Strong expression of this factor has better survival(124-126). 
CD 117: 
Its expression indicates high risk of tumor proliferation and aggressivity. 
Oncogene expression: 
Increased expression of RAS, p21 and NMYC predicts poor prognosis. 
P53 and HER2neu: 
P53 and HER2neu overexpression is associated with poor prognosis. 
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RECOMMENDATIONS BY IASLC/ATS/ERS NEW MULTIDISCIPLINARY 
INTERNATIONAL CLASSIFICATION, FOR SMALL BIOPSY AND 
CYTOLOGY SPECIMENS WERE: 
• For cytology as well as small biopsy specimens, if  a clear differentiation can be 
done,  which satisfies the standard morphologic criteria, further specific typing 
of NSCLC into squamous cell carcinomas and adenocarcinomas can be done 
with morphology alone. 
• The term  NSCLC - NOS  must be  used as infrequently as possible and  it 
should only be used if the  diagnosis cannot be made out by morphology and /or 
by  special staining / IHC. 
• When  small biopsy / cytology specimen is used  in addition  with special stains 
for diagnosis, it should be clearly noted whether the diagnosis is achieved with 
only  light microscopy or in combination with special stains. 
• The term non-squamous cell carcinoma which is used by clinicians, should not 
be used by pathologists while reporting. Pathologists should report  NSCLC  
only as ADC , SQCC and  NSCLC - NOS. 
• The tissue specimens  received by pathologists should  be used judiciously and 
preserved to the maximum, as more tissues will be needed for further molecular 
studies(127-129) 
• In small biopsies / cytology specimens,  if any invasive pattern is found in 
adenocarcinoma ,it is to be reported as a lepidic  growth pattern . The term 
minimally invasive ADC and ADC- in situ  should not be used. 
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• The term large cell carcinoma,  should be used  only in  resected specimens as  
thorough  sampling of  tumour is not possible in small biopsy/cytology 
specimens. 
• • If the tumor shows sarcomatoid features characterised by malignant giant 
cells or spindle cells with nucleus showing  pleomorphism, it  should be 
classified according to guidelines above as  NSCLC favouring ADC or NSCLC 
favouring  SCC based on features of  glandular pattern or squamous features  
respectively. when these features are absent   it is to be reported as NSCLC - 
NOS with a word about sarcomatoid features.. 
• Only if  the tumor shows neuro endocrine morphology, neuro endocrine  IHC  
markers are performed. 
• Further classification of  NSCLC- NOS is possible with the use of IHC, into 
NSCLC favouring ADC  and NSCLC favouring SCC. 
• It is advised to use minimal stains for further subclassification of   NSCLC-
NOS.  
• It is recommended to use only one marker  for adenocarcinoma or one marker 
for squamous cell carcinoma.  
• Currently, the single best marker for diagnosing  adenocarcinoma is  TTF-1. 
Staining with diastase - periodic acid schiff,  alcian blue/ PAS stains  or 
mucicarmine  also play a role in diagnosing adenocarcinoma. 
• The specific marker for diagnosing  SCC is Polyclonal  p40  rather  than the 
monoclonal p63 . p40 is likely to surpasses p63 as a best IHC  marker in 
diagnosing   squamous cell carcinoma. 
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• In  NSCLC -NOS , the cases which shows  TTF-1 positive and /or mucin 
positive, but  p40 and p63 negative are termed as NSCLC favouring 
adenocarcinoma. similarly those cases with p40 and/or p63 positive but TTF-1 
and mucin stain negative are termed as NSCLC favouring SCC with comment 
on whether special stains are used  to arrive at diagnosis. 
• In case, one population of tumour cells show TTF-1 reactivity and another 
population  of tumor cells show positive for squamous cell markers, possibility 
of adenosquamous carcinoma should be considered. 
• But if  TTF-1 as well as p40 are negative  and fails to show any squamous or 
glandular morphology, the diagnosis still remains as NSCLC-NOS. 
ALTERATIONS SUGGESTED BY IASLC/ERS/ATS INTERNATIONAL 
CLASSIFICATION OF LUNG MALIGNANCY IN RESECTED 
SPECIMENS: 
(ANNEXURE IV) 
1.  The term bronchoalveolar carcinoma  is discarded. 
In the new multidisciplinary classification,  BAC is discarded. Originally, 
broncho alveolar carcinoma  is defined as a non-invasive lesion, but since then, it is 
used to denote broad  group  of tumours which includes 
• Nonmucinous BAC. This is defined as solitary non invasive  small  
peripheral adenocarcinoma. This type will have 100% 5 year survival 
rate(130) 
41 
 
• Minimally invasive  small peripheral adenocarcinoma with 5 year survival 
upto 100%(131,132) 
• Invasive adenocarcinoma with mixed subtype. 
• Nonmucinous  and mucinous  adenocarcinoma, which is known as BAC  
earlier. 
• Advanced mucinous adenocarcinoma( stage 4) with low survival rate. 
• In the new multidisciplinary  classification, ‘BAC’ is referred to as 
"former BAC" 
 2.  New concepts were introduced for 
• Small  solitary peripheral  adenocarcinoma  with  size less than or equal to 
3cm,with pure lepidic growth  without invasion with 100% disease 
specific survival as adenocarcinoma in situ(AIS). 
• Small, solitary peripheral adenocarcinoma with size less than or equal to 
3cm, with predominantly lepidic growth with invasion, with 100% disease 
specific interval  as minimally invasive adenocarcinoma(MIA). 
3. Former invasive adenocarcinoma with mixed subtype is replaced by predominant 
pattern..   
• According  to 2004 WHO classification more than 90% of lung 
adenocarcinoma are of mixed subtypes. In this new  international 
classification this mixed subtype is replaced with  predominant pattern. It 
is recommended to choose one  predominant pattern  based on  recording 
of  patterns in 5% increments. 
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4. In multiple lung adenocarcinoma patients it is recommended comprehensive 
histological subtyping of  heterogenous, complex lung adenocarcinoma to determine 
if the tumours  are synchronous, metachronous or metastasis. 
5. It recommends  the term lepidic predominant adenocarcinoma in place of  
previously classified  as mixed subtype ,predominantly non mucinous BAC. 
6. New histological type of  Micropapillary predominant adenocarcinoma is 
introduced . This is associated with poor prognosis. 
7. In new international classification,  invasive mucinous adenocarcinoma, fetal, 
enteric and colloid adenocarcinomas are introduced as new variants. 
Acccording to Edwards et al , only  10-15% of  lung cancer  patients undergo 
resection and the preoperative diagnosis confirmed. So treatment for  most of the  
patients  is based on diagnosis with small biopsy/cytology  specimens alone. 
According to Suprun et al, 
• The criteria for diagnosis of  SCC are  
The presence of Keratin formation  and/or Intercellular bridges. In case if  the 
tumor lacks such features, the intraepithelial in- situ like extensions along the 
bronchus are present in SCC.  Both  adeno and small cell carcinoma  do not replace 
the bronchial epithelium to a considerable extent.  And most of these cases are either 
well differentiated or moderately differentiated. This feature aids in  histological 
typing of lung cancers in small biopsy specimens. 
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The grading of squamous cell carcinoma cannot be done in small biopsy specimens. 
• The diagnosis of adenocarcinoma seems to be more challengeable as the presence 
of mucin and gland formation are frequently not present in small biopsies, which 
calls for mucin stains to demonstrate the presence of glandular elements. 
• According to the study of  Edwards et al, the diagnosis of large cell carcinoma is 
possible only with  resected specimens and not on  small biopsies. This is because,  
they are the  poorly differentiated forms of adenocarcinoma, squamous cell 
carcinoma, or neuroendocrine carcinoma  and also most major types of lung cancers 
contain foci of features of  large cell carcinoma . 
• Recent data showed that the high percentage (30-50%) of  NSCLC-NOS  has been 
diagnosed in small biopsies. Data from the registry of epidemiology surveillence 
shows   the increasing frequency of this diagnosis. 
EPIDERMAL GROWTH FACTOR RECEPTOR 
EGFR is a trans-membrane glycoprotein belonging to erbB family of closely 
related receptor tyrosine kinases. It has a transmembrane protein binding 
extracellularly and intracellular tyrosine kinases and other regulatory domains. On 
binding of specific ligands, normally functioning EGFR undergoes conformational 
change and phosphorylation causing signal transduction and cell proliferation and 
inhibition of apoptosis(133). 
           The advent of EGFR receptor tyrosine kinase inhibitors gefinitb and erlotinib 
has revolutionized the treatment of lung cancer patients in advanced cases. A large 
phase III trial ofnearly 1700 advanced lung cancer patients treated with gefitinib or 
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placebo was conducted. It did not have survival benefit for all patients treated with 
lung cancer(134). However, there was a significant survival advantage in non-smoking 
Asian women with adenocarcinoma historical type.It has been estimated that EGFR 
is most likely expressed in solid growth pattern which suggest that there is a strong 
association between EGFR amplification and aggressiveness. 
It is suggested that EGFR expression can be arrested by IHC, PCR and F1SH. 
Positive predictive values for each of them are 6.5-8.2%, 7-100% and 11-89%(133) 
respectively. 
IHC as tool for diagnosis: 
           Paraffin blocks with 4 mm serial sections(135) from surgical biopsy specimens 
or cytology cell blocks can be used for EGFR protein expression. Chromogen is used 
to identify positive result in diaminobenzidine. 
Negative internal control can be provided by normal epithelial and stroma 
IHC scoring for EGFR is as follows. 
Tumour cell staining membrane is considered to be specific for the 
interpretation of the tumour. 
Score 0 is given for tumours that has no staining of tumour cells, score 1 weak 
membrane staining in more than 10% of tumor cells, score 2 for moderate staining in 
more than 10% of tumor cells and score 3 for tumor cells with strong intensity in 
more than 10% of tumour cells. 
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IHC done for EGFR has approximate sensitivity of 88% and specificity of 
88%. Squamous cell carcinoma is said to have strong staining with more number of 
positive tumor cells than adenocarcinoma. 
It is estimated that IHC positive tumors show strong EGFR expression 
whereas IHC negative tumors have low or no expression. 
The introduction of targeted therapies has greatly revolutionized the treatment 
of advanced lung carcinomas. Two oral drugs which are used to inhibit EGFR are 
Gefitinib & Erlotinib and they have been recently approved for use in advanced non-
small cell lung cancer. Hence clinical, morphological and molecular factors can 
predict the response rate to these drugs. However standardization of techniques and 
more studies regarding this concept are expected in future. 
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MATERIALS AND METHODS 
This study is a retrospective study of lung cancers in large resected specimens 
and small biopsies conducted in the Institute of pathology,Madras Medical College 
and Rajiv Gandhi Government General Hospital, Chennai during the period between 
July 2013 to June 2015. 
A total of 33042  cases were submitted to our department the Institute of 
pathology, Madras medical college during the period of July 2013 to June 2015 for 
histopathological examination. Out of them, 412 were lung cases. Among them 39 
cases were pneumonectomy specimens, 67 were lobectomy specimens and 306 were 
small biopsies (Transbronchial, Endobronchial, Open, Ultrasound  guided biopsies 
and Computed tomography guided core biopsies). 
INCLUSION CRITERIA: 
• All lobectomy specimens of lung cancer 
• All small biopsies of lung cancer 
 EXCLUSION CRITERIA: 
• Benign lesions 
• other non neoplastic lesions  
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METHOD OF DATA COLLECTION 
Detailed history of the patients regarding age, sex, site, tumor location, 
radiological findings, FOB findings, cytological findings were obtained for all the  
cases. Out of these 
Material Inadequate for opinion         -     42 
Non neoplastic lesions                     -     137 
Suspicious of malignant cells       -      40 
Malignancy                 -      193 
 
Among the malignant cases, 
NSCLCs           - 178 cases 
Small cell lung carcinoma          -          9 
Others         - 6 
 
 These 178 cases of Non small cell lung carcinoma cases were reviewed and 
sub classified  on the basis of H&E morphology according to WHO criteria for 
classification . Tumours were sub typed as adenocarcinoma  if  it  has features of  
gland formation and/ or mucin production, squamous cell carcinoma if it has features 
of  keratinazation or intercellular bridges and  large cell carcinoma  ( undifferentiated 
non small cell carcinoma)  if  it lacked  both  glandular  or  squamous patterns.  Out 
of these 178 cases, 77 cases are Squamous cell carcinoma, 63 cases are 
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adenocarcinoma, 38 cases are NSCLC-NOS which includes poorly differentiated 
carcinoma 9 cases are small cell carcinoma and 4 cases are neuroendocrine 
carcinoma. 
Among all these cases 20 cases of squamous cell carcinoma, 20 cases of  
Adenocarcinoma, 20 cases of NSCLC - NOS were randomly selected for study 
purpose. 
All  60 cases of  non small cell lung carcinomas (NSCLC)  which were 
selected randomly  were included  for  further evaluating and comparing  the clinical 
and morphological parameters and to study the efficency of   marker 
 (EGFR). Various clinical parameters like age, sex, site, location of tumor, 
radiological findings, cytology and histopathological diagnosed were assessed. 
 Five micron thick paraffin sections were cut and procedures were done for 
IHC study of EGFR. 
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IMMUNOHISTOCHEMICAL EVALUATION: 
 
Antigen Vendor Species Dilution 
Positive 
control 
EGFR Pathnsitu Rabbit Ready to use 
Lung 
squamous cell 
carcinoma 
 
Immunohistochemistry was done as per protocol given in ANNEXURE V. 
INTERPRETATION AND SCORING SYSTEM: 
 The immunohistochemically stained slides were analyzed for the presence of 
reaction, cellular localization(membrane), percentageof cells stained and intensity of 
reaction. 
 In this study, for evaluation of EGFR protein,  expression greater  than 10%  
of the  tumour cells by the tumour marker  is considered as positive. Cases  with no 
focal areas of positive staining and with less than 10% staining are considered 
negative. (ANNEXURE VI). 
 
  
 
 
50 
 
 
STATISTICAL ANALYSIS: 
 
The clinicopathological relationship with EGFR expression was analysed by 
Chi-square test. 
           The statistical analysis for this study was carried out via SPSS software, 
version 21     .  
           The p values of less than 0.05  is considered to be stastically significant. 
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OBSERVATION AND RESULTS 
In my study period of two years from july 2013 to june 2015, a total of 33042 
specimens were obtained in the Institute of Pathology, Madras Medical College for 
histopathological examination. 
Totally 412 lung specimens were reveived. Out of these   188   are small 
biopsies and     5  are resected specimens. 
It is shown in (TABLE :1 CHART :1). 
 
TABLE 1: TYPES OF LUNG SPECIMEN 
 
 
 
 
 
 
 
 
Total Percentage 
Small biopsies 188 97.40% 
Resected specimens 5 2.59% 
Total 193 100% 
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         Apart from this metastatic carcinoma constitutes 12 cases and carcinoid 
constitutes 4 cases with 2%. 
 
TABLE:3, CHART:3 
TABLE 3: HISTOLOGICAL TYPES OF LUNG CARCINOMA 
HPE DIAGNOSIS Total Percentage 
Adenocarcinoma 64 33.01 
Carcinoid 4 2.07 
LCC 2 1.04 
NSCLC-NOS 37 19.17 
SCC 77 39.90 
Small cell ca 9 4.66 
Grand Total 193 100.00 
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          In this study, with the available radiological details, mass lesions and opacity 
are proved to be malignant. Some cases which are diagnosed as non-neoplastic 
lesions radiologically such as cavitary lesions, consolidation changes etc also turned 
out to be malignant pathologically. 
(TABLE:9 CHART:9) 
CHART 9: VARIOUS RADIOLOGICAL FINDINGS IN LUNG CANCER 
XRAY,CT,MRI Total Percentage 
Cavity 1 0.52 
Collapse 1 0.52 
Consolidation 1 0.52 
Mass 164 85.42 
Opacity 9 4.69 
Pleural based lesion 10 5.21 
Pleural effusion 6 3.13 
Grand Total 192 100.00 
 
          Most common radiological finding was found to be mass lesion which 
constitutes 164 cases making a total percentage of 85.42%.  other less common 
findings are cavity, collapse and consolidation which constitutes only0.5% of cases 
each. 
(TABLE :10 CHART:10) 
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According to WHO classification, Non-small cell lung carcinoma are divided 
into Squamous cell carcinoma, Adenocarcinoma, NSCLC-NOS. In our 
study,Squamous cell carcinoma is the most common type which accounts for 
39.90% with the total of 193 in our 2 years study. Adenocarcnima constitutes 
63(32.64%), NSCLC-NOS constitutes 37 cases(19.17%). 
(TABLE:14 CHART:14) 
 
TABLE 14:NON SMALL CELL LUNG CARCINOMA SUB TYPE 
ACCORDING TO WHO  CLASSIFICATION 
HPE DIAGNOSIS Total Percentage 
Adenocarcinoma 63 32.64 
NSCLC-NOS 37 19.17 
SCC 77 39.90 
Grand Total 193 100.00 
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The distribution of EGFR in various histological types of non-small cell lung 
cancer was compared and it was estimated that 18 cases of  adenocarcinoma, 8 cases 
of poorly NSCLC-NOS and 5 cases of SCC  were found to be positive for EGFR 
expression.2 cases of Adenocarcinoma, 12 cases of NSCLC-NOS and 5 cases of 
SCC were found to be  negative for EGFR expression. 
(TABLE:20 CHART:20) 
TABLE 20: DISTRIBUTION OF EGFR IN NON SMALL  
CELL LUNG CANCER 
HPE Diagnosis NEG EGFR Neg Pos EGFR pos 
Grand 
Total 
Adenocarcinoma 2 10.53 18 43.90 20 
NSCLC-NOS 12 63.16 8 19.51 20 
SCC 5 26.32 15 36.59 20 
Grand Total 19 100 41 100 60 
p value - 0.002277393 
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FIGURE 4: SQUAMOUS CELL CARCINOMA-LUNG 
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FIGURE  5 : MODERATELY DIFFERENTIATED SQUAMOUS CELL 
CARCINOMA 100X HPE NO: 3071/15 
 
FIGURE  6  : MODERATELY DIFFERENTIATED SQUAMOUS CELL 
CARCINOMA  400X HPE NO: 3071/14 
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FIGURE 7 : MODERATELY DIFFERENTIATED  
ADENOCARCINOMA 100X HPE NO. 99/15 
 
FIGURE 8  : MODERATELY DIFFERENTIATED  
ADENOCARCINOMA 400X HPE NO. 99/15 
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FIGURE 9  :  NON SMALL CELL LUNG CARCINOMA-NOS 
100X HPE NO.   3225/15 
 
 
FIGURE 10  : NONSMALL CELL LUNG CARCINOM-NOS 
400X HPE NO. 3225/15 
 
  
EGFR EXPRESSION 
 
FIGURE 11 : STRONG MEMBRANE POSITIVITY OF EGFR IN  
ADENOCARCINOMA 100 X HPE NO.98/15 
 
 
FIGURE 12 : STRONG MEMBRANE POSITIVITY OF EGFR IN  
ADENOCARCINOMA 400 X HPE NO. 98/15 
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FIGURE 13 : STRONG MEMBRANE STAINING OF EGFR IN  
SQUAMOUS CELL CARCINOMA 100 X HPE NO. 312/15 
 
FIGURE 14    : STRONG MEMBRANE STAINING OF EGFR IN  
SQUAMOUS CELL CARCINOMA 100 X HPE NO. 312/15 
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FIGURE 15 : BRONCHIAL WASH;   PLEOMORPHIC MALIGNANT  
CELLS IN GROUPS AND IN SINGLES. CYTOLOGY NO. 1264/15 
 
 
FIGURE 16  : LYMPH NODE FNAC; METASTATIC SCC  
DEPOSITS IN LYMPH NODE 400X FNAC NO. 1544/15 
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DISCUSSION 
Worldwide, lung cancer is the most common cause of cancer and cancer 
related Mortality and the common chemotheraupeutic drugs which are used today do 
not have adequate Efficacy and specificity. 
 Lung cancer is more predominant in males which constitutes 10.9% of all 
cases of Cancer and it constitutes around 13% of all cancer related mortality.  
Lung cancer is more predominant in 4th to 6th dacade of life. Also the prognosis of 
lung cancer is very poor.  
Among all the histological types of lung carcinoma, more than 85% are non 
small cell lung cancer. Adenocarcinoma is the most common type of lung carcinoma. 
Until the recent past, the histological subclassification has no clinical or theraupeutic 
significance. But recently with the advent of newer drugs and targeted therapies, it is 
very essential to subtype non small cell lung cancer because it has direct effect on 
treatment and prognosis. 
Non small cell lung cancer has to be subclassified accurately into squamous 
cell Carcinoma, adenocarcinoma, non small cell lung cancer-NOS. It is necessary to 
classify them as EGFR expression should be tested in adenocarcinoma and other 
types of lung cancer as EGFR tyrosine kinase inhibitors form the primary treatment 
for adenocarcinoma lung. 
Most of the lung cancers are in advanced stage at presentation. So the 
resection rate is very low most which in probably 15-20% of cases and targeted 
therapies are the mainstay of treatment for such cases. 
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Madras medical college is a tertiary referral centre and institute for 
pathology.This is a retrospective study of  lung cancers conducted for two years 
between july 2013 to june 2015. A total of 193 lung cancer specimens were found in 
this study period among the total 412 lung specimens received . Among the entire 
lung cancer specimens, 33.25% of cases are non neoplastic and 46.84% of cases are 
malignant. More than 85% of lung cancers in my study is nonsmall cell lung cancer. 
Small cell lung carcinoma accounts for 4.66% of cases. This is in accordance with 
the study done by Navada S et al which states that around 80-85% of lung cancer 
cases are non small cell lung carcinoma and thus it is the most common type. 
 Most of the lung cancers present in the age group between 50-80 years of age 
with a percentage of 77.88%. less then 3% of cases are seen in the age group less 
than 30 years. This is in correlation with the study done by Delik Erman et al(136) and 
others. The median age group in our study is 55 years. 
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Median age of lung cancer compared in various studies compared with the 
current study 
Study Median age 
Xu J et al(137) 58 
Jing C et al(138) 62 
Zhang J et al(139) 61 
Yin X et al(140) 61 
Current study 55 
 
In our study lung cancer is more common in males with a percentage of 
76.17. ItObserved that the incidence of lung cancer in squamous cell carcinoma and 
adenocarcinoma areMore common among males. But females are more commonly 
affected by adenocarcinoma than by squamous cell carcinoma. This is accordance 
with the study conducted by Churg AM et al(141).A study by Kiyohara et al(142) has 
estimated that the ability of DNA repair is relatively low in Females when compared 
to males and they are said to have increased susceptibity for lung cancer. 
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Pecerntage of gender distribution in other studies compared with the current 
study 
 Cases(n) MALES(%) FEMALES(%) 
An S et al(143) 524 361(68.89%) 163(31.10%) 
Liu Y et al(144) 251 138(54.98%) 113(45.01%) 
Feng Q et al(145) 309 184(59.54%) 125(40.45%) 
Sun L et al(146) 301 174(57.80%) 127(42.19%) 
current study 193 147(76.17%) 46(23.83%) 
 
Cough is the most common presenting symptom in our study with a  
percentage of 56.99. The other common symptoms are hemoptysis and 
breathlessness with 27.46% and 11.92% respectively. According to the study 
conducted by Bach PB et al(147), the common symptoms are cough, hemoptysis, 
breathlessness, hoarseness of voice, significant loss of weight and recurrent 
respiratory infections like bronchitis, pneumonia. 
          Most of the time, the symptoms of lung cancer are not specific. In many 
patients, the Lung cancer has already spread beyond the origin site by the time they 
seek medical attention. 
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 In our study 55.44% of cases are smokers and 44.04% of the cases are non 
smokers. Squamous cell carcinoma is strongly associated with smoking with 44%. 
And most of the adenocarcinoma patients are non smokers with 35%. This is in 
accordance with the study conduceted by Satcher D et al(148) who estimated that 
smoking is the most common cause for both males and females and it is more 
strongly associated with squamous cell carcinoma.          
Comparison of smoking incidence in various studies with the current study 
Studies Cases(n) Smokers(%) Nonsmokers(%) 
Li Y et al(149) 208 130(62.5%) 78(37.5%) 
Lai Y et al(150) 697 366(52.91%) 331(47.48%) 
Zhang J et al(139) 454 279(61.45%) 175(38.54%) 
Sun L et al(146) 301 173(57.47%) 128(42.52%) 
current study 193 187(55.44%) 85(44.04%) 
 
In our study, squamous cell carcinoma is the most common histological 
subtype of lung Cancer with 39.90% followed by adenocarcinoma which is 33.01%. 
the recent study by Lortet et al(151)in 2014 has stated that adenocarcinoma incidence 
is on the increasing side and it has surpassed those of SCC though historically SCC 
is the most common subtype. 
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Comparison of histological subtypes with various studies: 
HISTOLOGICAL 
SUBTYPES 
Voporciyan AA et 
al(152) 
Delik Erman et 
al(136) 
current study 
Adenocarcinoma 40% 20-30% 33.01% 
Squamous cell 
carcinoma 
30% 40-60% 39.90% 
Large cell carcinoma 9% 5-10% 1.04% 
Small cell lung 
cancer 
10-15% 5-15% 4.66% 
Carcinoid <5% 5% 2.07% 
 
Squamous cell carcinoma: 
In our study, squamous cell carcinoma is the most common type of nonsmall 
cell lung cancer. It is diagnosed histologically based on the keratinformation and the 
appearance ofintercellular bridges. These specific features arenot seen in other 
carcinomas such as adenocarcinoma or small cell carcinoma. 
Among the 193 malignant cases in our study, 77 cases come under this 
category with a percentage of 39.90% and showed a male predominance with 
62cases with a percentage of  80.51%.  
           Out of the total 77 cases of squamous cell carcinoma, 44 cases are smokers 
with a percentage of 41.12%. 37.67% of cases are non smokers. 
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Adenocarcinoma : 
In our study, next to squamous cell carcinoma, adenocarcinoma is the most 
Common subtype. The presence of glandular features and mucin production are the 
characteristic features of this subtype. 
Out of the total 193 malignant cases, 33.01% of cases come under this 
category(n=64). Out of the 64 cases 41 cases are males and 22 cases are females with 
a 65.07% and 34.92% respectively. 
The most common radiological finding is the presence of mass  lesion which 
has a total of 164 cases with 85.42%. the other radiological findings are opacity, 
pleural effusion and pleural based lesion. This is in accordance with the study 
conducted by Minna, JD et al. 
Right upper lobe is the most common site of involvement in our study with 
45.08%(n=87). It is followed by left upper lobe with 24.35%. The right lung is more 
commonly involved than the left lung with 63.73% and 36. 26% respectively. This is 
in accordance with the study done by Vivekanand N et al in which right lung cancers 
are more common than the cancers of left lung. 
Expression of EGFR: 
Lung cancer is the leading cause of cancer related mortality in industrialised 
Countries. Most of the cases present with advanced disease. It is therefore essential 
to identifyThe prognostic factors and treatment modalities for effective management. 
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EGFR plays an important role in motility, invasion and angiogenesis of 
tumourCells. It is thus considered to be a poor prognostic factor for survival in non 
small lung cancer. 
EGFR positivity among non small cell lung cancers: 
In our randomly selected 60 cases of non small cell lung cancer, 68.33% of 
cancers arepositive for EGFR expression. The various studies results are as follows, 
 EGFR positivity 
Gao J et al(153) 36.7% 
Sun LN et al(146) 32.9% 
She Juan An et al(154) 28.4% 
Feng Q et al(145) 22.2% 
Yuanyang Lai et al(155) 33.7% 
Current study 68.33% 
 
Comparison of EGFR expression in males and females in other studies 
compared with the current study: 
In our study, EGFR seems to be increasingly expressed among females with a 
percentage of 90.48. 46.15% of the males are positive for EGFR expression. This is 
in accordance with the study done by ShuaiWang et al(156), a meta analysis study  
which statesthat EGFR expression is significantly low in females. 
This variable is statistically significant in our study as indicated by the p value 
0.000613(p<0.05) obtained by t test. 
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 EGFR expression in males and females in other studies compared with our 
study: 
 FEMALES MALES 
Yan Liu et al(157) 63.7% 49.3% 
Yuan Yang Lai et al(155) 57.5% 22.7% 
Ying Li et al(158) 47.5% 15% 
Feng Q et al(145) 39.2% 30.4% 
current study 90.48% 46.15% 
 
Comparison of EGFR expression among smokers and non smokers: 
It is estimated in our study that 96.67% of the EGFR positive cases are 
nonsmokers. This is in accordance with the study conducted by Yaxiong Zhang et 
al(159). This study states that EGFR positive patients are never smokers which is 
defined as the persons who smoked less than 100 cigarettes in his lifetime. 
 Smokers Nonsmokers 
Yingli et al(158) 13.9% 42.3% 
She Juan An et al(154) 12.4% 40.9% 
Feng Q et al(145)  40.2% 
Yuanyang et al(155) 30.3% 37.5% 
current study 40% 96.67% 
 
        This is statistically significant in our study p value of 0.0000023(p<0.05) 
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Agewise distribution of EGFR: 
In our study, 29.27% of the EGFR positive patients are in the age group 
between 51 and 60 years. 73.17% of the cases are less than 60 years of age and 
26.83% of the patients are above 60 years. The study by Yuanyang et al(155) says that 
37.3% of the patients are above 60 years of age and 30.7% of the patients are less 
than 60 years of age. Studies by Feng Q et al has suggested that most EGFR positive 
patients are less tha 60 years. This variable is not statistically significant in our study 
with a p value of 0.146071(p>0.05). 
EGFR expression in various histological subtypes: 
In our study, EGFR expression is more commonly seen in adenocarcinoma 
with a percentage of 43.90%. 36.59% of squamous cell carcinomas are positive for 
EGFR expressionand 19.51% of NSCLC-NOS are positive foe EGFR expression. 
The comparison with various studies are as follows 
 Adenocarcinoma Squamous cell 
carcinoma 
NSCLC-NOS 
Yan Liu et al(160) 61.1% 29.7% 40% 
Yuanyang Lai et 
al(155) 
52.9% 14.5%  
Ying Li et al(158) 44.2% 8% 
She Juan An et 
al(154) 
40.3% 4.4%  
Feng Q et al(145) 38.8%   
Our study 43.90% 36.59% 19.51% 
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The comparison of EGFR distribution with various histological subtypes is 
statisticallySignificant in our study with p value of 0.00227393(p<0.05). 
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Limitations of the study: 
• These patients are selected from the tertiary care centre and it is not a 
population basedStudy. Hence the study population might not represent the 
general population 
• Gene expression profiling gives more accurate values than the 
immunohistochemistry.Since it is expensive, it cannot be applied to all the 
patients. 
• Since this is a retrospective study, targeted therapy was not given. Hence the 
prognosticInfluence cannot be ascertained. 
  
  
 
SUMMARY 
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SUMMARY 
 This study on lung cancer is a retrospective study conducted in theInstitute 
of Pathology, MADRAS MEDICAL COLLEGE, Chennai during the 
period of july2013 to june 2015. 
 Among the total 412 lung specimens received, 137 cases are non 
neoplastic, 40 cases are suspicious of malignancy and193 cases are 
malignant. 
 Among the 193 malignant cases, 97.405 of the cases are small biopsiesand 
2.59% of the cases are resected specimens. The types of small biopsies 
reveived are CTguided biopsy, bronchial biopsy, transbronchial biopsy 
and USG guided biopsy. 
 Among the malignant cases, 178 cases are non small cell lung cancer 
Which vastly outnumber small cell lung carcinoma cases(9). 
 The distribution of squamous cell carcinoma and adenocarcinoma 
are39.90% and 33.01% respectively. Squamous cell carcinoma is more 
commonly seen in thanAdenocarcinoma, NSCLC-NOS accounts for 
19.17% of cases. 
 The mean age of presentation of lung cancer is 55.15 years. The youngest 
age at presentation is 29 years. 
 Among the 193 malignant cases, 76.17% of the cases are men and23.83% 
of the cases are women with increased incidence of squamous cell 
carcinoma in men and adenocarcinoma seen more commonly in women. 
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 Cough is the most common presenting complaint with 56.99% followedby 
breathlessness and hemoptysis. 
 The most common location of tumour is the right upper lobe. Right lungis 
more commonly involved than the left lung. 
 85.42% of the patients present with mass radiologically. The non 
neoplastic radiological findings like cavity and collape have turned to be 
malignant in few cases. 
 55.44% of the cases are smokers and 44.04% of the cases arenonsmokers 
with strong smoking association in squamous cell carcinoma with  41.1% 
 Sixty cases of non small cell lung cancer are randomly selected fromeach 
cateogory for EGFR expression by IHC. 68.33% of the cases are positive 
for EGFR expression.90.48%  of the females are positive for EGFR 
expression and 46.15%of the males showed positivity with p value-  
0.000613 
 96.67% of the EGFR positive cases are smokers and 40%  areare non 
smokers. p value-  0.0000023 
 29.27% of the EGFR positive patients are in the age group between51 and 
60 years. 
 Among the EGFR positive histological subtype, adenocarcinoma is the 
most common type with 43.90% followed by squamous cell carcinoma 
with 36.59% & NSCLC-NOS with 19.51%. p value-  0.0022. 
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PATIENT CHARACTERISTICS 
CHARACTERISTICS NUMBER % 
AGE   
<60 129 66.84% 
>60 64 33.16% 
GENDER   
Male 147 76.17% 
Female 46 23.83% 
SMOKING STATUS   
Never 107 55.44% 
Ever 85 44.04% 
HISTOLOGY   
Adenocarcinoma 64 33.01% 
SCC 77 39.90% 
NSCLC-NOS 37 19.17% 
LCC 2 1.04% 
Carcinoid 4 2.07% 
 
n=193 
 
 
 
90 
 
CHARACTERISTICS IN RELATION TO EGFR: 
CHARACTERISTICS NUMBER % p-value 
AGE    
<60 30 73.17% 0.146071 
>60 11 26.83% 
GENDER    
Male 18 46.15% 0.000613 
Female 21 90.48% 
SMOKING STATUS    
Never 29 96.67% 0.0000023 
Ever 12 40% 
HISTOLOGY    
Adenocarcinoma 18 43.90% 0.0027 
SCC 15 36.59% 
NSCLC-NOS 8 19.51% 
 
n = 60 
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CONCLUSION 
As most of the lung cancer cases present at advanced age, the introduction of 
targeted therapies particularly EGFR has revolutionise the treatment of lung cancer 
patients. 
                 There is a heightened interest in targeted therapy against lung cancers 
particularlyNon small cell lung cancer. The identification of EGFR expression gives 
a fascinating opportunity for the development of tyrosine kinase inhibitors against 
non small cell lung cancers. 
               It is very clear from the comparison of various studies from our studies that 
EGFR expression is more common in females, never smokers and adenocarcinoma 
histological type. 
EGFR, being a poor prognostic factor, its expression is very important to 
identify the tyrosine kinase inhibitors sensitivity. 
              Hence it is very important to find the association between EGFR expression 
and its clinocopathological parameters in order to select the patients for targeted 
therapy like erlotinib, gefitinib for advanced lung cancers. 
              In conclusion, it is recommended that EGFR expression should be a routine 
test  after lung resection for all non small lung carcinoma especially adenocarcinoma 
and squamous cell carcinoma for better treatment for the patients. 
  
 
ANNEXURES 
  
 ANNEXURE-I 
 
PROFORMA 
 
Case number    :                               Name      : 
HPE number     :                               Age        :  
IP number        :                                                  Sex         : 
Clinical diagnosis :  
Complaint              : 
Radioimaging        : 
FOB findings         : 
Site of lesion          :  Right upper lobe/middle lobe/lower lobe 
                                     Left upper lobe/hilum/lower lobe 
Specimen   : CT guided biopsy/Bronchial biopsy/USG guided  
    biopsy/Open biopsy 
MICROSCOPY :   
Special stain : 
IHC 
EGFR           : Positive / Negative   
 
DIAGNOSIS          : 
 
Malignant epithelial tumours 
Squamous cell carcinoma  
          Papillary 
          Clear cell 
          Small cell 
Basaloid 
 
Small cell carcinoma  
Combined small cell carcinoma  
 
Adenocarcinoma  
Adenocarcinoma, mixed subtype  
Acinar adenocarcinoma  
         Papillary adenocarcinoma  
Bronchioloalveolar carcinoma  
Nonmucinous 
                    Mucinous  
Mixed nonmucinous and mucinous or              
indeterminate Solid adenocarcinoma with 
mucin  production  
Fetal adenocarcinoma  
Mucinous (“colloid”) carcinoma  
Mucinous cystadenocarcinoma 
Signet ring adenocarcinoma  
                    Clear cell adenocarcinoma  
 
Large cell carcinoma  
Large cell neuroendocrine carcinoma  
Combined large cell neuroendocrine carcinoma 
Basaloid carcinoma  
Lymphoepithelioma-like carcinoma  
Clear cell carcinoma  
Large cell carcinoma with rhabdoid phenotype  
 
Adenosquamous carcinoma 
 
Sarcomatoid carcinoma  
Pleomorphic carcinoma  
Spindle cell carcinoma  
Giant cell carcinoma  
Carcinosarcoma 
Pulmonary blastoma 
 
Carcinoid tumour  
Typical carcinoid  
Atypical carcinoid  
 
Salivary gland tumours 
Mucoepidermoid carcinoma  
Adenoid cystic carcinoma  
Epithelial-myoepithelial carcinoma  
 
Preinvasive lesions 
        Squamous carcinoma in situ 
        Atypical adenomatous hyperplasia 
Diffuse idiopathic pulmonary neuroendocrine cell 
hyperplasia 
 
Mesenchymal tumours 
Epithelioidhaemangioendothelioma 
Angiosarcoma 
Pleuropulmonaryblastoma 
Chondroma 
Congenial peribronchialmyofibroblastic tumour  
Diffuse pulmonary lymphangiomatosis 
Inflammatory myofibroblastic tumour  
Lymphangioleiomyomatosis 
Synovial sarcoma  
Monophasic  
Biphasic  
Pulmonary artery sarcoma  
Pulmonary vein sarcoma  
 
Benign epithelial tumours 
Papillomas 
Squamous cell papilloma  
Exophytic 
Inverted  
Glandular papilloma  
Mixed squamous cell and glandular papilloma  
Adenomas 
Alveolar adenoma  
Papillary adenoma  
Adenomas of the salivary gland type 
Mucous gland adenoma 
Pleomorphic adenoma  
Others 
Mucinous cystadenoma 
 
Lymphoproliferative tumours 
Marginal zone B-cell lymphoma of the MALT type  
Diffuse large B-cell lymphoma  
Lymphomatoidgranulomatosis 
Langerhans cell histiocytosis 
 
Miscellaneous tumours 
Harmatoma 
Sclerosinghemangioma 
Clear cell tumour  
Germ cell tumours 
Teratoma, mature  
Immature  
Other germ cell tumours 
Intrapulmonary thymoma 
Melanoma  
Metastatic tumours 
ANNEXURE : II 
WHO CLASSIFICATION FOR LUNG CANCER 
ANNEXURE : III 
PROPOSED IASLC/ATS/ERS CLASSIFICATION FOR SMALL 
BIOPSIES/CYTOLOGY 
2004 WHO Classification SMALL BIOPSY/CYTOLOGY: 
IASLC/ATS/ERS 
ADENOCARCINOMA       
Mixed subtype 
Acinar 
Papillary 
Solid 
Morphologic Adenocarcinoma 
pattern clearly 
presents:Adenocarcinoma, describe 
identifiable patterns present 
(including micropapillary pattern not 
included in 2004 WHO 
classification) 
No 2004 WHO counterpart – most 
will be solid adenocarcinomas 
Morphologic adenocarcinoma 
patterns not present (supported by 
special stains): Non-small cell 
carcinoma, favor adenocarcinoma 
Bronchioloalveolar carcinoma        
(nonmucinous) 
Adenocarcinoma with lepidic pattern 
(if pure, add note: an invasive 
component cannot be excluded) 
Bronchioloalveolar carcinoma       
(mucinous) 
Mucinous adenocarcinoma (describe 
patterns present) 
Fetal Adenocarcinoma with Fetal pattern 
 Mucinous (colloid) Adenocarcinoma with colloidal 
pattern 
Signet Ring  Adenocarcinoma with (describe 
patterns present) and signet ring 
features 
Clear cell Adenocarcinoma with (describe 
patterns present) and clear cell 
features 
SQUAMOUS CELL CARCINOMA   
Papillary         
Clear cell         
Small cell        
Basaloid 
Morphologic squamous cell pattern 
clearly presents: 
Squamous cell carcinoma 
No 2004 WHO counterpart Morphologic squamous cell patterns 
not present (supported by stains): 
Non-small cell carcinoma, favor 
squamous cell carcinoma 
SMALL CELL CARCINOMA 
 
Small cell carcinoma 
LARGE CELL CARCINOMA Non-small cell carcinoma, not 
otherwise specified (NOS) 
Large cell neuroendocrine 
carcinoma (LCNEC) 
Non-small cell carcinoma with 
neuroendocrine (NE) morphology 
(positive NE markers), possible 
LCNE 
Large cell carcinoma with N 
morphology(LCNEM) 
Non-small cell carcinoma with NE 
morphology (negative NE markers) – 
see comment  
Comment: This is a non-small cell 
carcinoma where LCNEC is 
suspected, but stains failed to 
demonstrate NE differentiation. 
ADENOSQUAMOUS 
CARCINOMA 
Morphologic squamous cell and 
adenocarcinoma patterns present: 
Non-small cell carcinoma, NOS, 
(comment that glandular and 
squamous components are present 
No counterpart in 2004 WHO 
classification 
Morphologic squamous cell or 
adenocarcinoma patterns present and 
stains are conflicting (TTF1 and p63 
positive) or suggest the other pattern 
is also present Non-small cell 
carcinoma, NOS, comment that 
glandular and squamous 
differentiation seen by IHC) 
Comment (for either setting): this 
could represent adenosquamous 
carcinoma. 
Sarcomatoid carcinoma Poorly differentiated NSCLC with 
spindle and/or giant cell carcinoma 
(mention if adenocarcinoma or 
squamous carcinoma are present) 
 
 
 
 
 
 
ANNEXURE:IV 
IASLC/ATS/ERS CLASSIFICATION OF LUNG 
ADENOCARCINOMA IN RESECTION SPECIMENS 
PREINVASIVE  LESIONS 
A typical adenomatous hyperplasia 
Adenocarcinoma in situ (≤3 cm formerly BAC)  
              -Nonmucinous 
              -Mucinous       
              -Mixed Mucinous/Non-Mucinous 
MINIMALLY INVASIVE ADENOCARCINOMA (≤3 cm lepidic 
predominant tumor with ≤5 mm invasion) 
              -Non mucinous       
              -Mucinous     
              -Mixed Mucinous/Non-Mucinous 
INVASIVE ADENOCARCINOMA 
Lepidic predominant (formerly non-mucinous BAC pattern, with >5 mm 
invasion)  
Acinar predominant  
Papillary predominant  
Micropapillary predominant  
Solid predominant with mucin production 
VARIANTS OF INVASIVE ADENOCARCINOMA   
Invasive mucinous adenocarcinoma (formerly mucinous BAC)  
Colloid  Fetal (low and high grade)  
Enteric 
ANNEXURE-V 
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 μ were cut from formalin fixed paraffin 
embedded tissue samples and transferred to gelatin-chrome alum 
coated slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections were deparaffinised in xylene for 15 minutes x 2 
changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes for 
2 changes. 
5. Then the sections were washed with tap water for 10 minutes. 
6. The slides are then immersed in distilled water upto 5 minutes. 
 
Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. This 
step unmasks the antigenic determinants of fixed tissue sections. 
2. The slides were then cooled to room temperature for 20 minutes and 
washed with tap water for 5 minutes. 
3. The slides were then rinsed with distilled water for 5 minutes. 
4. then the slides were washed with appropriate wash buffer (phosphate 
buffer) for 5 minutes x 2 changes. 
5. Peroxidase block was then applied for 10 minutes. 
6. The slides then were washed in phosphate buffer for 5 minutes x 2 
changes. 
7. Sections were covered with protein block for 5 minutes. 
 
 
 Antibody application: 
1. The sections were drained (without washing) and appropriate primary 
antibody is applied and incubated for 30 minutes. 
2. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
3. The slides were covered with Primary antibody amplifier for 10 
minutes. 
4. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
5. The slides were covered with HRP micropolymer Quanto for 10 
minutes. 
6. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of DAB 
Quantochromogen to 1 ml of DAB Quanto buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
3. wash the slides then in distilled water for 2 minutes. 
4. counterstain  the section with Hematoxylin  for 2 seconds. 
5. wash the slides in running tap water for 5 minutes. 
6. air dry the slides, cleared with xylene and mounted with DPX. 
 
Alternate methods of antigen retrieval 
• Pressure cooker antigen retrieval 
• Microwave and trypsin antigen retrieval 
 
  
ANNEXURE VI 
GRADING OF EGFR: 
0 – negative, no detectable staining. 
1+  faint membrane staining in more than 10% of tumour cells. 
2+  moderate and continuous membrane staining in more than 10% of 
tumour cells. 
3+ strong and continuousmembrane staining in more than 10% of 
tumour cells. 
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KEY TO MASTER CHART 
HPE NO : Histopathological examination number 
 M  : Male 
 F               :  Female 
Site  
1  : Right upper lobe 
2  : Right middle lobe 
3  : Right lower lobe 
4  : Left upper lobe 
5  : Left lower lobe 
6  : Left hilum 
Smoking  
Y              : Yes 
N              : No 
C/F          : Clinical Features 
1  : Cough 
2  :  Hemoptysis 
3  :  Breathlessness 
4  : Chest pain 
5  : Weight loss 
Radiological features: 
M              : Mass 
ME       : Mediastinal invasion 
PE         : Pleural effusion 
CN        : Cervical node metastasis 
MNI      : Ipsilateralmediastinallymphnode involvement 
MNC     : Contralateral mediastinallymphnode involvement 
O      : Opacity 
F         : Fibrosis 
CON         : Consolidation 
CAV         : Cavity 
SCN         : Supraclavicular lymphnode metastasis 
RIB          : Rib erosion 
P              : Polypoidal lesion 
SP            : Sputum 
BW          : Bronchial wash 
PF           : Pleural fluid 
NEG       : Negative 
         POS       : Positive 
Specimen: 
 1  : Computed tomogram guided biopsy 
 2  : Bronchial biopsy 
 3  : Transbronchialbipsy 
 4  : Ultrasonogram guided biopsy 
           5          :         Resected specimens 
HPE diagnosis : Histipathological examination diagnosis 
A   : Adenocarcinoma  
S     : Squamous cell carcinoma 
NSCLC-NOS  :        Non small cell lung cancer-not otherwise Specified. 
C  :        Carcinoid 
LCC                :        Large Cell Carcinoma 
P                      :        Poorly differentiated carcinoma. 
 
INFORMATION SHEET 
 
Title : A study of expression of EPIDERMAL GROWTH      
FACTOR RECEPTOR(EGFR) in Lung Cancers 
 
Your specimen has been accepted. 
• We are conducting a study on lung cancersamong patients attending Institute of 
Pathology, Madras Medical College,Chennai and for that your specimen may be 
valuable to us. 
• The purpose of this study is to diagnose the expression of a special marker (EGFR) in 
lung cancers. 
• We are selecting certain cases and if your specimen is found eligible, we may be using 
your specimen to perform extra tests and special studies which in any way do not 
affect your final report or management. 
• The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
• Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
• The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management or 
treatment. 
 
 
 
Signature of investigator     Signature of participant 
 
 
 
Date:  
 
 
 
INFORMED CONSENT FORM 
 
Title of the study:  A study of expression of EPIDERMAL GROWTH  FACTOR  
RECEPTOR(EGFR) in Lung  Cancers 
 
Name of the Participant : 
Name of the Principal (Co-Investigator) : 
Name of the Institution : Institute of Pathology, Madras Medical College. 
Name and address of the sponsor / agency (ies) (if any) : 
 
Documentation of the informed consent 
 
I _____________________________ have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a participant in 
 
“A study of expression of EPIDERMAL GROWTH  FACTOR  RECEPTOR(EGFR) in Lung  
Cancers” 
 
I have read and understood this consent form and the information provided to me. 
1. I have had the consent document explained to me. 
2. I have been explained about the nature of the study in which the resected endometrial tumors will 
be subjected to immunohistochemistry and histopathological examination. 
3. I have been explained about my rights and responsibilities by the investigator. I have the right to 
withdraw from the study at any time. 
4. I have been informed the investigator of all the treatments I am taking or have taken in the past 
________ months including any native (alternative) treatment. 
5. I hereby give permission to the investigators to release the information obtained from me as result 
of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and IEC. I 
understand that they are publicly presented. 
6. I have understand that my identity will be kept confidential if my data are publicly presented 
7. I have had my questions answered to my satisfaction. 
8. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. By signing 
this consent form I attest that the information given in this document has been clearly explained to me 
and understood by me, I will be given a copy of this consent document. 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
Name _________________________ Signature_________________ Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature_________________ Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________ Date________________ 
